Praxis Precision Medicines, Inc.

What they do

Praxis is a fully integrated CNS precision neuroscience company developing therapies for disorders of neuronal excitation-inhibition imbalance. It uses two platforms: Cerebrum, for orally available small molecules, and Solidus, for antisense oligonucleotides. The clinical portfolio includes ulixacaltamide for essential tremor, relutrigine for SCN2A/SCN8A DEEs, vormatrigine for focal onset seizures, and elsunersen for SCN2A DEE. The company has no approved products and has not generated product revenue.

Revenue drivers

• Ulixacaltamide (essential tremor) — NDA accepted with PDUFA date of January 29, 2027; if approved, would be the first therapy for essential tremor and is the lead commercial candidate.
• Relutrigine (SCN2A/SCN8A DEEs) — NDA under priority review with updated PDUFA date of December 27, 2026; if approved, would be the first therapy for these indications and eligible for a Pediatric Review Voucher.
• Vormatrigine (focal onset seizures) — In Phase 3 ENERGY program with five studies (EMPOWER, RADIANT, POWER1, POWER2, POWER3); no near-term revenue expected.
• Collaborations — UCB in-licensed PRAX-020 (KCNT1); a July 2026 collaboration with Remagine Labs to develop a transdermal ulixacaltamide patch; no collaboration revenue reported.

Recent performance

For the second quarter of 2026, Praxis reported zero revenue and cash and investments of approximately $1.4 billion, which management says maintains runway into 2028. Net loss for 2025 was $303.0 million, with operating cash flow of -$249.1 million. The company has not generated revenue in recent quarters; revenue in 2024 was $8.6 million, likely from collaboration, but 2025 revenue was $0.00. FDA completed BIMO inspections for both NDAs with no Form 483 issued.

Strategy

Praxis is preparing for commercial launch of ulixacaltamide and relutrigine, with commercial leadership in place, field force hiring underway, and distribution networks established. The company is expanding the ulixacaltamide franchise through a transdermal patch collaboration with Remagine Labs. It continues to advance the Solidus ASO platform, with three preclinical programs (PRAX-080, PRAX-090, PRAX-100) expected to nominate development candidates in the first half of 2026. The vormatrigine ENERGY program is ongoing, with POWER2 continued based on lessons from POWER1.

Risks

• No approved products or revenue — Praxis has incurred losses since inception and has no commercial products; it may need additional funding beyond current runway into 2028.
• Regulatory approval uncertainty — NDA reviews for ulixacaltamide and relutrigine are ongoing; FDA extended relutrigine review by three months, and there is no guarantee of approval.
• Clinical trial risks — Late-stage trials (e.g., vormatrigine ENERGY program) may fail to show efficacy or safety, and patient enrollment could be delayed.
• Competition and market size — Markets for product candidates may be smaller than expected, and competitors may develop safer or more effective therapies.

Outlook

Management expects PDUFA decisions for ulixacaltamide (January 29, 2027) and relutrigine (December 27, 2026), with no advisory committee meetings planned. Topline results from the EMERALD study of relutrigine in broad DEEs are anticipated in Q4 2026, which could support an sNDA in 2027 if positive. The company anticipates designating development candidates for three Solidus ASO programs in the first half of 2026. Commercial preparations are accelerating for both potential launches.